For the year ending 2025-12-31, ONCO had $4,574,154 increase in cash & cash equivalents over the period. -$9,678,390 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -14,032,342 |
| Loss on impairment of goodwill | 11,512,000 |
| Amortization of debt discount | 124,084 |
| Loss on extinguishment of note payable | 5,384,719 |
| Loss on extinguishment of series c preferred stock | 196,244 |
| Loss on issuance of preferred stock and warrants | 3,674,329 |
| Depreciation and amortization | 15,170 |
| Net periodic pension benefit cost | -619,399 |
| Stock-based compensation | 74,267 |
| Change in fair value of contingent warrant liabilities | 16,499 |
| Change in fair value of series d warrant liability | 10,377,638 |
| Change in fair value of series d derivative liability | 3,809,333 |
| Change in fair value of series e warrant liability | -4,486,847 |
| Change in fair value of series e derivative liability | 1,539,014 |
| Change in fair value of subscription agreement liability | 3,127,962 |
| Loss on disposal of property and equipment | -17,283 |
| Gain on forgiveness of accounts payable | 944,694 |
| Accounts receivable | 268,685 |
| Inventory | 73,720 |
| Investor receivable | 50,000 |
| Prepaid expenses and other assets | 128,360 |
| Deferred offering costs | 225,000 |
| Accounts payable | -1,093,655 |
| Accrued expenses | -580,032 |
| Loss on impairment of entadfi | 0 |
| Loss on impairment of intangibles | 0 |
| Amortization of debt discount - related party | 0 |
| Deferred tax benefit | 0 |
| Amortization of deferred offering costs | 0 |
| Gain on settlement of contingent warrant liabilities | 0 |
| Prepaid expenses, long-term | 0 |
| Loss on impairment of inventory of entadfi | 0 |
| Net cash used in operating activities | -9,678,390 |
| Proceeds from issuance of notes payable | 1,335,875 |
| Payment on note payables | 7,111,548 |
| Payment of redemption of series c preferred stock | 1,713,570 |
| Proceeds from issuance of series d preferred stock and warrants | 9,301,200 |
| Proceeds from issuance of series e preferred stock and warrants | 6,250,000 |
| Proceeds from issuance or sale of common stock | 6,391,655 |
| Cash in lieu of shares | 926 |
| Proceeds from issuance of notes payable - related party | 0 |
| Payment of financing costs | 0 |
| Proceeds from exercise of preferred investment options, net | 0 |
| Proceeds from exercise of stock options | 0 |
| Proceeds from exercise of warrants | 0 |
| Proceeds from issuance of series c preferred stock and warrants | 0 |
| Net cash provided by financing activities | 14,452,686 |
| Effect of exchange rate changes on cash | -200,142 |
| Purchase of property and equipment | 0 |
| Net cash used in investing activities | 0 |
| Net increase (decrease) in cash | 4,574,154 |
| Cash, beginning of period | 646,500 |
| Cash, end of period | 5,220,654 |
Onconetix, Inc. (ONCO)
Onconetix, Inc. (ONCO)